A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2014
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Lymphoma; Myeloma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 26 Jul 2011 Additional lead trial centers identified and company added in association field as reported by ClinicalTrials.gov.
- 02 Aug 2007 Drug name changed from AP 23573 to deforolimus (INN).